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Streptokinase was shown to cause extensive dissolution of thrombi in all but two of the 12 patients studied, sometimes within 12 hours but in one patient not until after six days of continuous infusion.
Methods and aims of laboratory control were discussed (Kakkar et al, 1969) and the side effects of each treatment described. Two fatal cases of retroperitoneal haemorrhage occurred in the heparin-treated group. There was only one other case of severe bleeding, an increased menstrual flow in a patient receiving streptokinase, and this was easily controlled. Most of the patients given streptokinase, but not those in the other groups, developed a pyrexia sometimes with rigors. One patient suffered a serious allergic reaction after a small part of the loading dose of streptokinase had been given; this responded to an antihistamine and hydrocortisone and the infusion was continued with ultimately complete dissolution of the thrombus.
Full results of the trial will be reported elsewhere. AB Kabi, Stockholm) into the pulmonary artery (eight patients) or right atrium (one patient). In all patients single-plane (anteroposterior) serial pulmonary arteriograms were obtained before treatment and repeated, sometimes on two occasions, at times varying from 24 hours to a month after starting treatment. In all but one patient an indwelling pulmonary artery catheter permitted repeated haemodynamic measurements during treatment and was used for the infusion of streptokinase, generally a dose of 600,000 IU for the first half hour followed by 100,000 IU/hour thereafter. The results were as follows: 2 Chronic pulmonary thromboembolism. Three patients with a history of longer duration were treated with streptokinase. In one, embolism had occurred six weeks previously, in another repeated emboli had probably occurred over weeks or months, and the third patient had a left pulmonary artery thrombosis at the site of an attempted delayed embolectomy for massive embolism occurring three months previously. In none was there any haemodynamic improvement when studied shortly after completing treatment and angiographic improvement was at the most slight in two and absent in the third patient.
3 Minor recent pulmonary embol. In two such patients streptokinase infusion was followed by complete disappearance of the filling defects seen on the pulmonary arteriograms when these were repeated at two and three days respectively. Complications of treatment included bleeding from skin incisions, haematoma formation, haematuria, and vaginal bleeding.
The indications for streptokinase in treating pulmonary embolism are not yet clear. Encouraging results were obtained in acute massive pulmonary embolism and these patients were spared embolectomy. Nonetheless there will be patients in whom the delay in response associated with streptokinase therapy is unacceptable and in whom embolectomy may be life-saving. Little benefit was obtained in three patients with thromboembolism of longer duration but resolution of minor recent emboli was demonstrated within three days in two patients. There is an urgent need for a controlled trial of streptokinase and of heparin therapy in such patients. Newcastle-upon-Tyne) The use of thrombolytic agents in coronary thrombosis has been based on the experimental work of Ruegsegger, Nydick, Hutter, Freiman, Bang, Cliffton, and LaDue (1959) . They described the lysis by streptokinase of thrombi artificially produced in the coronary arteries of dogs and showed that this lytic agent also substantially modified the histological appearances of the infarcts which followed the thrombosis. The lytic treatment had, however, to be given within three hours Evidence was presented as to why it is difficult to institute treatment early and of how large is the initial and hitherto unavoidable mortality. It is suggested therefore that the thrombolytic approach to coronary thrombosis may prove to be more successful when based on the prophylactic enhancement of the fibrinolytic activity of the blood of susceptible persons.
Surgery and Radiology, Withington Hospital, Manchester) This paper describes our experiences over the past 18 months with streptokinase in the treatment of the severely ischaemic limb.
Initially, we used thrombolytic therapy in 11 cases of poor risk advanced atherosclerotics who presented with severe pain at rest and incipient gangrene. Many had been treated unsuccessfully or successfully for a time with direct arterial surgery, lumbar sympathectomy etc, and were presenting with the end result of a long battle to preserve their peripheral circulation. Four were given intravenous streptokinase, 1-2 million units over a 24-hour period; the other seven were given a continuous intraarterial perfusion for 48 hours during which they received a total dose of streptokinase of between 0-25 to 0 75 million units. In this first series of 11 cases, our results were uniformly disappointing: we had two deaths, five major amputations, and the remaining four cases initially showed slight improvement but relapsed within six weeks. The twelfth patient was a 47-year-old obese woman who had undergone a pelvic operation and had postoperatively developed a massive collapse of the left lung with peripheral circulatory collapse. She was hypotensive and lay on her side for a considerable period of time. Twelve hours after operation she was found to have an ischaemic painful left hand with ascending oedema of the arm and absent radial and brachial pulses. A stellate ganglion block and anticoagulants did not improve her condition over the next eight hours. A long Teflon catheter was threaded in retrograde fashion via the right femoral artery into the aortic arch and its tip engaged in the origin of the left subclavian artery. Two million units of Kabikinase in 2 litres of normal saline to which 2,400 mg ,of lincomycin was added was infused over 18 hours. Ten hours later a faint radial pulse appeared and by 15 hours the colour of her hand improved considerably, the acute pain was diminished, and the radial pulse was full and bounding. Her subsequent recovery was uneventful and with physiotherapy she regained the full use of her hand by the end of three weeks.
Thereafter we tried to standardize our regimen of thrombolytic therapy in arterial thrombosis. First we restricted streptokinase perfusion to the cases of acute or acute-on-chronic thrombotic episodes. Secondly, in the acute cases, we gave a continuous intraarterial perfusion over 24 to 48 hours of a litre of normal saline containing 1-2 million units of Kabikinase and 1,200 mg of lincomycin every 12 hours. Thirdly, in the less urgent acute-on-chronic episodes, we gave a continuous intraarterial perfusion for 48 to 72 hours during which thrombolytic therapy was given intermittently by alternating, each 12 hours, a litre of normal saline containing streptokinase and lincomycin with a litre of Lomodex (low molecular weight dextran 40,000) containing thymoxamine (Opilon) 160 mg and lincomycin 1,200 mg.
Initially we used hydrocortisone systemically before and during perfusion but subsequently found this was not necessary. We did not use any laboratory control.
Of the last 36 cases, 11 showed side reactions of variable degree but none warranted discontinuation of perfusion. The complications broadly fell into two main groups. Firstly, bleeding at the site of arterial puncture (six cases) ranging from ecchymosis (two cases), persistent ooze (two cases), subcutaneous extravasation (one case), to haematoma (one case). Secondly, pyrexia over 100°F in five cases which persisted during perfusion only; this was not troublesome except in one patient who had rigors, arthralgia, and pain in the back which lasted during perfusion.
